Correlation
The correlation between HALO and ABBV is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
HALO vs. ABBV
Compare and contrast key facts about Halozyme Therapeutics, Inc. (HALO) and AbbVie Inc. (ABBV).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HALO or ABBV.
Performance
HALO vs. ABBV - Performance Comparison
Loading data...
Key characteristics
HALO:
0.58
ABBV:
0.83
HALO:
1.07
ABBV:
1.21
HALO:
1.19
ABBV:
1.19
HALO:
0.89
ABBV:
1.17
HALO:
2.15
ABBV:
2.66
HALO:
14.00%
ABBV:
9.07%
HALO:
51.35%
ABBV:
28.28%
HALO:
-74.26%
ABBV:
-45.09%
HALO:
-20.06%
ABBV:
-13.31%
Fundamentals
HALO:
$6.74B
ABBV:
$327.88B
HALO:
$3.78
ABBV:
$2.34
HALO:
14.48
ABBV:
79.32
HALO:
-2.50
ABBV:
0.40
HALO:
6.22
ABBV:
5.72
HALO:
13.91
ABBV:
230.90
HALO:
$1.08B
ABBV:
$57.37B
HALO:
$887.05M
ABBV:
$44.44B
HALO:
$699.60M
ABBV:
$16.36B
Returns By Period
In the year-to-date period, HALO achieves a 17.28% return, which is significantly higher than ABBV's 6.70% return. Over the past 10 years, HALO has underperformed ABBV with an annualized return of 12.04%, while ABBV has yielded a comparatively higher 15.54% annualized return.
HALO
17.28%
-8.71%
16.33%
29.34%
6.84%
18.23%
12.04%
ABBV
6.70%
-4.61%
3.65%
23.40%
12.26%
19.77%
15.54%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HALO vs. ABBV — Risk-Adjusted Performance Rank
HALO
ABBV
HALO vs. ABBV - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
HALO vs. ABBV - Dividend Comparison
HALO has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.43%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ABBV AbbVie Inc. | 3.43% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% | 2.54% |
Drawdowns
HALO vs. ABBV - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for HALO and ABBV.
Loading data...
Volatility
HALO vs. ABBV - Volatility Comparison
Halozyme Therapeutics, Inc. (HALO) has a higher volatility of 35.23% compared to AbbVie Inc. (ABBV) at 9.85%. This indicates that HALO's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
HALO vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HALO vs. ABBV - Profitability Comparison
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a gross profit of 216.46M and revenue of 264.86M. Therefore, the gross margin over that period was 81.7%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported a gross profit of 11.20B and revenue of 13.34B. Therefore, the gross margin over that period was 83.9%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported an operating income of 141.54M and revenue of 264.86M, resulting in an operating margin of 53.4%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported an operating income of 3.73B and revenue of 13.34B, resulting in an operating margin of 28.0%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Halozyme Therapeutics, Inc. reported a net income of 118.10M and revenue of 264.86M, resulting in a net margin of 44.6%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, AbbVie Inc. reported a net income of 1.29B and revenue of 13.34B, resulting in a net margin of 9.6%.